Novartis plans $600m investment in US R&D site
Novartis will invest $600m to expand its US R&D campus over the next five years to strengthen its position in US development hotspot.
Archives for October 27, 2010
Overseas FDA offices bring benefits but planning needed
Overseas FDA offices have realised immediate benefits but strategic planning is needed to ensure the ventures, critical aspects of the agency’s ability to ensure drug quality, are long-term successes according to the GAO.
SAGE Labs teams on preclinical Autism model development
SAGE Labs has unveiled plans to create rodent autism models for preclinical drug discovery and development in collaboration with advocacy group Autism Speaks.
B. Braun recalls heparin after OSCS detected
B. Braun is recalling lots of its injectable anticoagulant, Heparin, manufactured in 2008, after finding a sample used to manufacture Heparin Sodium USP active pharmaceutical ingredients (APIs) was contaminated.
Aoxing Pharma and Johnson Matthey form narcotics and neurological drug firm in China
Aoxing Pharma and Johnson Matthey team up to research, develop, manufacture and market active pharmaceutical ingredients (APIs) for narcotics and neurological drugs in China.
Endeavour sees recovery in intermediates sector
Drug industry demand for chemical intermediates and development projects has rebounded significantly in the last 12 months according to UK group Endeavour Specialty Chemicals.
Outsourcing a threat to supply chains, says PwC
Increased outsourcing carries a significant operational risk according to executives quizzed in a new survey by PwC and Axendia.